Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($1.15), $0.25 worse than the analyst estimate of ($0.90).

“First of all, I would like to sincerely thank all of those who are currently on the front lines of the COVID-19 pandemic. In addition, I would also like to recognize my Revance colleagues for their adaptability and resilience during these unprecedented times,” said Mark Foley, President and Chief Executive Officer. “As organizations adjust to the new world shaped by the COVID-19 pandemic, Revance does so from a position of financial, operational and product portfolio strength. We remain excited about the commercial potential for our RHA® dermal fillers in the U.S., which we now plan to launch in the third quarter of 2020, followed by DaxibotulinumtoxinA for Injection in glabellar lines, after an anticipated FDA approval on November 25. We also look forward to announcing the topline results from our Phase 3 trial in cervical dystonia and Phase 2 trial in plantar fasciitis in the second half. Despite the challenges that have resulted from the current pandemic, Revance remains on track to deliver on our key 2020 value drivers as we move into the back half of the year.”

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.